5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Anti-hypertensive Drugs market is segmented by Therapeutic Class (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Alpha Blockers, Renin Inhibitors, Calcium Channel Blockers, Other Therapeutic Classes), and Geography
2018 - 2026
Fastest Growing Market:
Certain factors that are driving the market growth include increasing prevalence of hypertension, growing initiatives by private and government organizations, and rising awareness about hypertension.
The prevalence of hypertension has observed a significant rise over the past few years. Generally, blood pressure rises and falls throughout the day. However, it can damage one’s heart and result in health problems, if it stays high for a long time. High blood pressure is called hypertension. High blood pressure is the most harmful factor when it comes to the risk of heart disease and stroke, which is the leading cause of death in the United States, as stated by the World Health Organization. According to the CDC (Centers for Disease Control and Prevention, 2017), about 75 million American adults (32%) have high blood pressure (hypertension), but only about half (54%) of people with high blood pressure have their condition under control. CDC also states that high blood pressure costs the nation USD 48.6 billion every year. This total includes the medications to treat high blood pressure, cost of health care services, and missed days of work.
Antihypertensive drugs are referred to as a class of drugs that are used in treating hypertension (high blood pressure). There are many classes of antihypertensive drugs, which have the ability to lower blood pressure by different means, and thus, prevent the complications associated with high blood pressure, including stroke and myocardial infarction.
|Angiotensin Converting Enzyme (ACE) Inhibitors|
|Angiotensin Receptor Blockers (ARBs)|
|Calcium Channel Blockers|
|Other Therapeutic Classes|
Report scope can be customized per your requirements. Click here.
Thiazide diuretics are the cornerstone of treatment for hypertension in most patients. Hydrochlorothiazide is the most commonly used thiazide diuretic in the United States. The Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure recommends thiazide-type diuretics to be one of the preferred drug treatments for hypertension, whether used on its own or along with other antihypertensive drugs, such as calcium channel blockers. Moreover, it was also noted that more than one-third of the adults affected by hypertension were reported to take diuretics.
To understand key trends, Download Sample Report
According to the AHA (American heart association), 74.9% of hypertension patients are currently undergoing treatment, and only 52.2% of patients have it under control. AHA projection shows that by 2030, about 41.4% of adults in the United States are expected to have hypertension.
The demand for prompt and accurate diagnosis, and treatment of hypertension, identifying people predisposed to the disease, presence of technically advanced healthcare infrastructure, and management of the prognosis of the disease are some of the key market drivers of the North American anti-hypertension market.
To understand geography trends, Download Sample Report.
The anti-hypertensive drugs market is highly competitive and consists of a number of major players. Companies, like Astrazeneca PLC, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd, Lupin Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited, and Sanofi SA, among others, hold the substantial market share in the anti-hypertensive drugs market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hypertension
4.2.2 Growing Initiatives by Private and Government Organizations
4.2.3 Rising Awareness about Hypertension
4.3 Market Restraints
4.3.1 Multiple Major Drug Patent Expiration
4.3.2 Side-effects of Treatment Options
4.3.3 Rise in Non-pharmacological Therapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Therapeutic Class
5.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors
5.1.3 Angiotensin Receptor Blockers (ARBs)
5.1.4 Beta Blockers
5.1.5 Alpha Blockers
5.1.6 Renin Inhibitors
5.1.7 Calcium Channel Blockers
5.1.8 Other Therapeutic Classes
5.2.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South korea
22.214.171.124 Rest of Asia-Pacific
5.2.4 Middle-East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East & Africa
5.2.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Boehringer Ingelheim
6.1.3 Daiichi Sankyo Company Limited
6.1.4 Johnson & Johnson Ltd
6.1.5 Lupin Limited
6.1.6 Merck & Co. Inc.
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Ranbaxy Laboratories Limited
6.1.10 Sanofi SA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments